OTCMKTS:BIOYF BioSyent (BIOYF) Stock Price, News & Analysis $10.18 0.00 (0.00%) As of 07/2/2026 03:06 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesBuy This Stock About BioSyent Stock (OTCMKTS:BIOYF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioSyent alerts:Sign Up Key Stats Today's Range$10.18▼$10.2650-Day Range$9.76▼$10.9552-Week Range$7.63▼$12.00Volume1,411 shsAverage Volume2,905 shsMarket CapitalizationN/AP/E Ratio50.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioSyent Inc. is a specialty biopharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products and medical devices. The company leverages expertise in regulatory affairs, clinical development and manufacturing to deliver a range of branded and generic therapies across multiple therapeutic areas, with particular emphasis on endocrine disorders, supportive care oncology and dermatology. BioSyent operates a manufacturing facility in Canada that supports both its proprietary portfolio and contract development and manufacturing services (CDMO) for small-molecule products. Its end-to-end capabilities—encompassing formulation, fill-finish and quality testing—serve clients in North America and selected international markets. The company's commercial footprint spans Canada and the United States, where it markets specialty pharmaceuticals through its dedicated sales force and distribution partnerships. BioSyent continues to bolster its product pipeline through strategic in-licensing, acquisitions and targeted internal development programs, aiming to address evolving patient needs in niche therapeutic segments. Guided by an experienced leadership team with backgrounds in pharmaceutical development and commercialization, BioSyent is focused on sustainable growth through portfolio expansion and manufacturing capacity enhancement. The company's strategy emphasizes high-value specialty products, positioning BioSyent to respond to emerging healthcare trends and regulatory opportunities.AI Generated. May Contain Errors. Read More Receive BIOYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIOYF Stock News HeadlinesBioSyent to Present at Planet MicroCap Las VegasJune 15, 2026 | globenewswire.comBioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)May 19, 2026 | globenewswire.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.July 5 at 1:00 AM | Weiss Ratings (Ad)BioSyent Declares Second Quarter 2026 DividendMay 14, 2026 | globenewswire.comBioSyent Releases Financial Results for First Quarter 2026May 14, 2026 | globenewswire.comBioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026May 7, 2026 | globenewswire.comBioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | globenewswire.comBioSyent Announces Grant of Restricted Share UnitsMarch 24, 2026 | globenewswire.comSee More Headlines BIOYF Stock Analysis - Frequently Asked Questions How have BIOYF shares performed this year? BioSyent's stock was trading at $9.52 on January 1st, 2026. Since then, BIOYF stock has increased by 6.9% and is now trading at $10.18. How do I buy shares of BioSyent? Shares of BIOYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/05/2026Next Earnings (Estimated)8/25/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:BIOYF CIKN/A Webwww.biosyent.com Phone(905) 206-0013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio50.02 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:BIOYF) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.